Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 67

1.

Inhibition of Allergic Reactivity through Targeting FcεRI-Bound IgE with Humanized Low-Affinity Antibodies.

Zhang K, Elias M, Zhang H, Liu J, Kepley C, Bai Y, Metcalfe DD, Schiller Z, Wang Y, Saxon A.

J Immunol. 2019 Dec 1;203(11):2777-2790. doi: 10.4049/jimmunol.1900112. Epub 2019 Oct 21.

PMID:
31636239
2.

Human Mast Cells From Adipose Tissue Target and Induce Apoptosis of Breast Cancer Cells.

Plotkin JD, Elias MG, Fereydouni M, Daniels-Wells TR, Dellinger AL, Penichet ML, Kepley CL.

Front Immunol. 2019 Feb 18;10:138. doi: 10.3389/fimmu.2019.00138. eCollection 2019.

3.

NF-κB inhibitors that prevent foam cell formation and atherosclerotic plaque accumulation.

Plotkin JD, Elias MG, Dellinger AL, Kepley CL.

Nanomedicine. 2017 Aug;13(6):2037-2048. doi: 10.1016/j.nano.2017.04.013. Epub 2017 Apr 27.

PMID:
28457935
4.

Antigenic Determinants of the Bilobal Cockroach Allergen Bla g 2.

Woodfolk JA, Glesner J, Wright PW, Kepley CL, Li M, Himly M, Muehling LM, Gustchina A, Wlodawer A, Chapman MD, Pomés A.

J Biol Chem. 2016 Jan 29;291(5):2288-301. doi: 10.1074/jbc.M115.702324. Epub 2015 Dec 7.

5.

Surface plasmon resonance: a label-free tool for cellular analysis.

Zeidan E, Kepley CL, Sayes C, Sandros MG.

Nanomedicine (Lond). 2015;10(11):1833-46. doi: 10.2217/nnm.15.31. Review.

PMID:
26080702
6.

Inhibition of inflammatory arthritis using fullerene nanomaterials.

Dellinger AL, Cunin P, Lee D, Kung AL, Brooks DB, Zhou Z, Nigrovic PA, Kepley CL.

PLoS One. 2015 Apr 16;10(4):e0126290. doi: 10.1371/journal.pone.0126290. eCollection 2015.

7.

Study examining fullerene toxicity raises questions as to the purity of the nanomaterials and erroneous experimental conclusions.

Kepley C, Dellinger A.

Toxicol Sci. 2014 Oct;141(2):326-7. doi: 10.1093/toxsci/kfu182. No abstract available.

8.

IL-33/ST2 axis promotes mast cell survival via BCLXL.

Wang JX, Kaieda S, Ameri S, Fishgal N, Dwyer D, Dellinger A, Kepley CL, Gurish MF, Nigrovic PA.

Proc Natl Acad Sci U S A. 2014 Jul 15;111(28):10281-6. doi: 10.1073/pnas.1404182111. Epub 2014 Jun 30.

9.

A steroid-mimicking nanomaterial that mediates inhibition of human lung mast cell responses.

Dellinger AL, Zhou Z, Kepley CL.

Nanomedicine. 2014 Aug;10(6):1185-93. doi: 10.1016/j.nano.2014.02.006. Epub 2014 Feb 22.

10.

Application of fullerenes in nanomedicine: an update.

Dellinger A, Zhou Z, Connor J, Madhankumar AB, Pamujula S, Sayes CM, Kepley CL.

Nanomedicine (Lond). 2013 Jul;8(7):1191-208. doi: 10.2217/nnm.13.99. Review.

PMID:
23837857
11.

A novel gadolinium-based trimetasphere metallofullerene for application as a magnetic resonance imaging contrast agent.

Adiseshaiah P, Dellinger A, MacFarland D, Stern S, Dobrovolskaia M, Ileva L, Patri AK, Bernardo M, Brooks DB, Zhou Z, McNeil S, Kepley C.

Invest Radiol. 2013 Nov;48(11):745-54. doi: 10.1097/RLI.0b013e318294de5d.

PMID:
23748228
12.

Functionalization of gadolinium metallofullerenes for detecting atherosclerotic plaque lesions by cardiovascular magnetic resonance.

Dellinger A, Olson J, Link K, Vance S, Sandros MG, Yang J, Zhou Z, Kepley CL.

J Cardiovasc Magn Reson. 2013 Jan 16;15:7. doi: 10.1186/1532-429X-15-7.

13.

Epoxyeicosatrienoic acids are involved in the C(70) fullerene derivative-induced control of allergic asthma.

Norton SK, Wijesinghe DS, Dellinger A, Sturgill J, Zhou Z, Barbour S, Chalfant C, Conrad DH, Kepley CL.

J Allergy Clin Immunol. 2012 Sep;130(3):761-769.e2. doi: 10.1016/j.jaci.2012.04.023. Epub 2012 Jun 2.

14.

In vitro desensitization of human skin mast cells.

Zhao W, Gomez G, Macey M, Kepley CL, Schwartz LB.

J Clin Immunol. 2012 Feb;32(1):150-60. doi: 10.1007/s10875-011-9605-8. Epub 2011 Oct 19.

15.

A potential new target for asthma therapy: a disintegrin and metalloprotease 10 (ADAM10) involvement in murine experimental asthma.

Mathews JA, Ford J, Norton S, Kang D, Dellinger A, Gibb DR, Ford AQ, Massay H, Kepley CL, Scherle P, Keegan AD, Conrad DH.

Allergy. 2011 Sep;66(9):1193-200. doi: 10.1111/j.1398-9995.2011.02614.x. Epub 2011 May 10.

16.

A novel class of compounds with cutaneous wound healing properties.

Zhou Z, Joslin S, Dellinger A, Ehrich M, Brooks B, Ren Q, Rodeck U, Lenk R, Kepley CL.

J Biomed Nanotechnol. 2010 Oct;6(5):605-11.

PMID:
21329053
17.

Fullerene antioxidants decrease organophosphate-induced acetylcholinesterase inhibition in vitro.

Ehrich M, Van Tassell R, Li Y, Zhou Z, Kepley CL.

Toxicol In Vitro. 2011 Feb;25(1):301-7. doi: 10.1016/j.tiv.2010.09.010. Epub 2010 Oct 1.

PMID:
20888407
18.

Liposomal formulation of amphiphilic fullerene antioxidants.

Zhou Z, Lenk RP, Dellinger A, Wilson SR, Sadler R, Kepley CL.

Bioconjug Chem. 2010 Sep 15;21(9):1656-61. doi: 10.1021/bc1001664.

19.

A new class of human mast cell and peripheral blood basophil stabilizers that differentially control allergic mediator release.

Norton SK, Dellinger A, Zhou Z, Lenk R, Macfarland D, Vonakis B, Conrad D, Kepley CL.

Clin Transl Sci. 2010 Aug;3(4):158-69. doi: 10.1111/j.1752-8062.2010.00212.x.

20.

C5a receptor enables participation of mast cells in immune complex arthritis independently of Fcγ receptor modulation.

Nigrovic PA, Malbec O, Lu B, Markiewski MM, Kepley C, Gerard N, Gerard C, Daëron M, Lee DM.

Arthritis Rheum. 2010 Nov;62(11):3322-33. doi: 10.1002/art.27659.

21.

Uptake and distribution of fullerenes in human mast cells.

Dellinger A, Zhou Z, Norton SK, Lenk R, Conrad D, Kepley CL.

Nanomedicine. 2010 Aug;6(4):575-82. doi: 10.1016/j.nano.2010.01.008. Epub 2010 Feb 4.

22.

Mitochondrial uncoupling protein 2 inhibits mast cell activation and reduces histamine content.

Tagen M, Elorza A, Kempuraj D, Boucher W, Kepley CL, Shirihai OS, Theoharides TC.

J Immunol. 2009 Nov 15;183(10):6313-9. doi: 10.4049/jimmunol.0803422. Epub 2009 Oct 21.

23.

Fullerene nanomaterials inhibit phorbol myristate acetate-induced inflammation.

Dellinger A, Zhou Z, Lenk R, MacFarland D, Kepley CL.

Exp Dermatol. 2009 Dec;18(12):1079-81. doi: 10.1111/j.1600-0625.2009.00904.x.

24.

Fullerene nanomaterials potentiate hair growth.

Zhou Z, Lenk R, Dellinger A, MacFarland D, Kumar K, Wilson SR, Kepley CL.

Nanomedicine. 2009 Jun;5(2):202-7. doi: 10.1016/j.nano.2008.09.005. Epub 2009 Feb 14.

PMID:
19223242
25.

Polyhydroxylated C60 fullerene (fullerenol) attenuates neutrophilic lung inflammation in mice.

Roursgaard M, Poulsen SS, Kepley CL, Hammer M, Nielsen GD, Larsen ST.

Basic Clin Pharmacol Toxicol. 2008 Oct;103(4):386-8. doi: 10.1111/j.1742-7843.2008.00315.x. No abstract available.

26.

Hydrochalarones: a novel endohedral metallofullerene platform for enhancing magnetic resonance imaging contrast.

MacFarland DK, Walker KL, Lenk RP, Wilson SR, Kumar K, Kepley CL, Garbow JR.

J Med Chem. 2008 Jul 10;51(13):3681-3. doi: 10.1021/jm800521j. Epub 2008 Jun 18.

27.

Crystal structure of a dimerized cockroach allergen Bla g 2 complexed with a monoclonal antibody.

Li M, Gustchina A, Alexandratos J, Wlodawer A, Wünschmann S, Kepley CL, Chapman MD, Pomés A.

J Biol Chem. 2008 Aug 15;283(33):22806-14. doi: 10.1074/jbc.M800937200. Epub 2008 Jun 2.

28.

IL-10 suppresses mast cell IgE receptor expression and signaling in vitro and in vivo.

Kennedy Norton S, Barnstein B, Brenzovich J, Bailey DP, Kashyap M, Speiran K, Ford J, Conrad D, Watowich S, Moralle MR, Kepley CL, Murray PJ, Ryan JJ.

J Immunol. 2008 Mar 1;180(5):2848-54.

29.

"Accentuate the negative, eliminate the positive": engineering allergy therapeutics to block allergic reactivity through negative signaling.

Saxon A, Kepley C, Zhang K.

J Allergy Clin Immunol. 2008 Feb;121(2):320-5. Epub 2007 Dec 20. Review.

PMID:
18086492
30.

Syk deficiency in human non-releaser lung mast cells.

Gomez G, Schwartz L, Kepley C.

Clin Immunol. 2007 Oct;125(1):112-5. Epub 2007 Aug 10. No abstract available.

31.

Fullerene nanomaterials inhibit the allergic response.

Ryan JJ, Bateman HR, Stover A, Gomez G, Norton SK, Zhao W, Schwartz LB, Lenk R, Kepley CL.

J Immunol. 2007 Jul 1;179(1):665-72.

32.

Modifications to an Fcgamma-Fcvarepsilon fusion protein alter its effectiveness in the inhibition of FcvarepsilonRI-mediated functions.

Allen LC, Kepley CL, Saxon A, Zhang K.

J Allergy Clin Immunol. 2007 Aug;120(2):462-8. Epub 2007 Jun 1.

PMID:
17543377
33.

Recent advances in the use of genetically engineered negative signaling molecules to treat allergic diseases.

Saxon A, Zhu D, Zhang K, Chan LA, Kepley CL.

Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M. 2006;(95):223-31; discussion 231-3.

PMID:
17393744
34.

Chimeric human fcgamma-allergen fusion proteins in the prevention of allergy.

Zhang K, Zhu D, Kepley C, Terada T, Saxon A.

Immunol Allergy Clin North Am. 2007 Feb;27(1):93-103. Review.

35.

New approaches to allergen immunotherapy.

Kepley CL.

Curr Allergy Asthma Rep. 2006 Sep;6(5):427-33. Review.

PMID:
16899206
36.

Fc gamma RIIa, not Fc gamma RIIb, is constitutively and functionally expressed on skin-derived human mast cells.

Zhao W, Kepley CL, Morel PA, Okumoto LM, Fukuoka Y, Schwartz LB.

J Immunol. 2006 Jul 1;177(1):694-701.

37.

TGFbeta1 induces mast cell apoptosis.

Norozian F, Kashyap M, Ramirez CD, Patel N, Kepley CL, Barnstein BO, Ryan JJ.

Exp Hematol. 2006 May;34(5):579-87.

PMID:
16647563
38.

IL-3-mediated TNF production is necessary for mast cell development.

Wright HV, Bailey D, Kashyap M, Kepley CL, Drutskaya MS, Nedospasov SA, Ryan JJ.

J Immunol. 2006 Feb 15;176(4):2114-21.

39.

Antigen-induced reduction in mast cell and basophil functional responses due to reduced Syk protein levels.

Kepley CL.

Int Arch Allergy Immunol. 2005 Sep;138(1):29-39. Epub 2005 Aug 8.

PMID:
16088210
40.

TGF-beta 1 inhibits mast cell Fc epsilon RI expression.

Gomez G, Ramirez CD, Rivera J, Patel M, Norozian F, Wright HV, Kashyap MV, Barnstein BO, Fischer-Stenger K, Schwartz LB, Kepley CL, Ryan JJ.

J Immunol. 2005 May 15;174(10):5987-93.

41.

A chimeric human-cat fusion protein blocks cat-induced allergy.

Zhu D, Kepley CL, Zhang K, Terada T, Yamada T, Saxon A.

Nat Med. 2005 Apr;11(4):446-9. Epub 2005 Mar 27.

42.

Genetically engineered negative signaling molecules in the immunomodulation of allergic diseases.

Saxon A, Zhu D, Zhang K, Allen LC, Kepley CL.

Curr Opin Allergy Clin Immunol. 2004 Dec;4(6):563-8. Review.

PMID:
15640700
43.

Inhibition of allergen-specific IgE reactivity by a human Ig Fcgamma-Fcepsilon bifunctional fusion protein.

Zhang K, Kepley CL, Terada T, Zhu D, Perez H, Saxon A.

J Allergy Clin Immunol. 2004 Aug;114(2):321-7.

PMID:
15316510
44.

Co-aggregation of FcgammaRII with FcepsilonRI on human mast cells inhibits antigen-induced secretion and involves SHIP-Grb2-Dok complexes.

Kepley CL, Taghavi S, Mackay G, Zhu D, Morel PA, Zhang K, Ryan JJ, Satin LS, Zhang M, Pandolfi PP, Saxon A.

J Biol Chem. 2004 Aug 20;279(34):35139-49. Epub 2004 May 19.

45.

IL-4 selectively enhances FcgammaRIII expression and signaling on mouse mast cells.

Chong HJ, Andrew Bouton L, Bailey DP, Wright H, Ramirez C, Gharse A, Oskeritzian C, Xia HZ, Zhu J, Paul WE, Kepley C, Schwartz LB, Ryan JJ.

Cell Immunol. 2003 Aug;224(2):65-73.

PMID:
14609572
46.

FcepsilonRI-FcgammaRII coaggregation inhibits IL-16 production from human Langerhans-like dendritic cells.

Kepley CL, Zhang K, Zhu D, Saxon A.

Clin Immunol. 2003 Aug;108(2):89-94.

PMID:
12921754
47.

Evidence for human mast cell nonreleaser phenotype.

Kepley CL, Cohen N.

J Allergy Clin Immunol. 2003 Aug;112(2):457-9. No abstract available.

PMID:
12897759
49.

Regulation of human basophil adhesion to endothelium under flow conditions: Different very late antigen 4 regulation on umbilical cord blood-derived and peripheral blood basophils.

Kepley CL, Andrews RP, Brown DC, Chigaev A, Sklar LA, Oliver JM, Larson RS.

J Allergy Clin Immunol. 2002 Sep;110(3):469-75.

PMID:
12209096
50.

Supplemental Content

Loading ...
Support Center